Last $2.25 USD
Change Today -0.03 / -1.32%
Volume 15.6K
As of 8:04 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

oragenics inc (OGEN) Snapshot

Open
$2.31
Previous Close
$2.28
Day High
$2.37
Day Low
$2.25
52 Week High
01/13/14 - $4.65
52 Week Low
04/22/14 - $2.07
Market Cap
81.3M
Average Volume 10 Days
21.9K
EPS TTM
$-0.57
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORAGENICS INC (OGEN)

Related News

No related news articles were found.

oragenics inc (OGEN) Related Businessweek News

No Related Businessweek News Found

oragenics inc (OGEN) Details

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. It develops and markets probiotic products comprising ProBiora3, an oral care probiotics that promote oral health for humans and pets under the Evora and ProBiora brands in approximately 13 countries worldwide. The company’s ProBiora3 products include flavored probiotic tablets, such as EvoraPlus and EvoraKids for daily use by adults and children; EvoraPet for companion pets, including cats and dogs; and EvoraPro, a product for the dental office channel. Its product candidates consists of LPT3-04, a naturally occurring compound for weight loss; SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay; and MU1140-S, an antibiotic product candidate in preclinical testing for healthcare-associated infections. Oragenics, Inc. offers its ProBiora3 products through direct-to-consumer channels, professional offices, and private label partnerships. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

9 Employees
Last Reported Date: 02/28/14
Founded in 1996

oragenics inc (OGEN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $311.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $200.8K
Vice President of Research & Development
Total Annual Compensation: $177.0K
Compensation as of Fiscal Year 2013.

oragenics inc (OGEN) Key Developments

Oragenics Inc. Appoints Al Fosmoe as Senior Vice President Operations/Product Development

Oragenics Inc. announced that Mr. Al Fosmoe has joined Oragenics as Senior Vice President Operations/Product Development. The appointment is directly related to the progress Oragenics has made in the development of a new pipeline of novel antibiotics from its lantibiotic platform, and marks the expansion of the team dedicated to accelerating the progress of the lantibiotic pipeline. Mr. Fosmoe brings to Oragenics more than 25 years of product development, regulatory and commercialization experience in the regulated healthcare products sector, including biologics and drugs. His background spans operational and regulatory oversight for the development of live biotherapeutic products (LBP), biotechnology-derived products, and various oral care products, as well as advancing drug candidates through US and EU clinical trials.

Oragenics Inc. Presents at RedChip Global Online CEO Conference, Apr-23-2014 09:00 AM

Oragenics Inc. Presents at RedChip Global Online CEO Conference, Apr-23-2014 09:00 AM. Speakers: John N. Bonfiglio, Chief Executive Officer, President and Director.

Oragenics Inc. to Amend its Articles of Incorporation

Oragenics Inc. at the annual general meeting to be held on May 30, 2014, proposed amendment to the company’s Articles of Incorporation to increase the number of authorized shares of common stock from 50 million to 100 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGEN:US $2.25 USD -0.03

OGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioGaia AB kr186.00 SEK -1.00
BLIS Technologies Ltd $0.02 NZD 0.00
View Industry Companies
 

Industry Analysis

OGEN

Industry Average

Valuation OGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 72.1x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 64.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORAGENICS INC, please visit www.oragenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.